ATOS

ATOSSA THERAPEUTICS, INC. - 10-Q Summary (Q2 2024)

Business Context and Reporting Period

Company: Atossa Therapeutics, Inc. (ATOS)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: A clinical-stage biopharmaceutical company focused on developing proprietary medicines for breast cancer and other breast conditions. The lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen. The company has no commercial revenue and relies on cash reserves and potential financing to fund operations.

Key Financial Metrics

Note: The company reported no revenue for any period presented. Interest income increased due to higher yields on money market accounts.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $3.8 million for the six months ended June 30, 2024, compared to the prior year period. This improvement was driven by a reduction in operating expenses and the absence of a $3.0 million impairment charge on an equity investment recorded in Q2 2023.
• Operating Expenses: Total operating expenses decreased by $0.8 million year-over-year for the six-month period.
  • R&D Expenses: Increased slightly by $0.1 million due to higher drug development costs, offset by a decrease in stock-based compensation.
  • G&A Expenses: Decreased by $0.9 million, primarily due to lower stock-based compensation and the absence of $0.6 million in severance costs for a former CFO incurred in 2023. However, legal fees and investor relations expenses increased.
• Liquidity: Cash and cash equivalents decreased by approximately $9.0 million during the six months ended June 30, 2024, reflecting ongoing operational burn.

Guidance, Outlook, and Risks

Outlook and Liquidity: Management believes current cash resources ($79.5 million) are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring losses and will need to raise substantial additional capital in the future through equity offerings, debt, or collaborations.

Clinical Progress:

• Karisma Study: Phase 2 study for women with mammographic breast density is fully enrolled; primary data expected in H2 2024.
• EVANGELINE Study: Phase 2 neoadjuvant trial for ER+/HER2- breast cancer is ongoing.
• I-SPY 2 Trial: Enrollment completed in January 2024; a new study arm combining (Z)-endoxifen with abemaciclib was expanded in June 2024.

Risks and Contingencies:

• Patent Litigation: Intas Pharmaceuticals filed a Post Grant Review (PGR) petition in August 2023 seeking to invalidate a key patent (U.S. Patent No. 11,572,334). The company is actively contesting this.
• Australian Tax Rebate: A liability of $1.8 million is recorded regarding the Australian R&D tax incentive program, as the company is no longer reasonably assured the full tax position would be sustained under audit.
• Capital Requirements: Failure to secure additional funding could force the company to curtail or suspend business plans.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $79.5 million cash balance against projected burn rates for the next 12 months, considering potential delays in clinical trials.
• Patent Status: Monitor the outcome of the Post Grant Review (PGR) filed by Intas Pharmaceuticals regarding the core (Z)-endoxifen patent.
• Clinical Data Readouts: Track the release of primary data from the Karisma study (expected H2 2024) and progress in the EVANGELINE and I-SPY 2 trials.
• Australian Tax Liability: Assess the potential for additional charges related to the $1.8 million accrued liability for Australian R&D rebates.
• Dilution Risk: Review the impact of outstanding warrants (21.2 million shares) and options (20.7 million shares) on future capital raises.